When comparing the driver genes such as CCND1, CCND3, NDS2/MMSET in each patient, we found that among the four MM with t(4;14) translocation, two patients (MM07, MM08) with VGPR showed dramatic reductions in FGFR3 expression after treatment, however other two patients with PR or stable disease (SD) (MM03 and MM10 respectively) showed this decrease in a less extent (Additional file 1: Fig. S7C). This evidence concerns the gene NSD2 and Miyoshi myopathy.